Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constantin Lapa

Showing results (221-230 of 269) with videos related to

Pageof 27
Sort By:
Theranostics|January 7, 2020
<sup>18</sup>F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular ImagingRudolf A Werner, Thorsten Derlin, Constantin Lapa, et al.
Molecular Imaging and Biology|May 30, 2019
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [<sup>18</sup>F]DCFPyL: Impact of Tumor Burden on Normal Organ UptakeRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Oncotarget|October 6, 2016
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneityRudolf A Werner, Constantin Lapa, Harun Ilhan, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine CarcinomasAlexander Weich, Rudolf A Werner, Andreas K Buck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 3, 2025
PET imaging utilization and trends in Germany: a comprehensive surveyAdrien Holzgreve, Dirk Hellwig, Henryk Barthel, et al.
Molecular Imaging and Biology|August 16, 2018
Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide TherapyRudolf A Werner, Harun Ilhan, Sebastian Lehner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2025
Biodistribution and Radiation Dosimetry for [<sup>68</sup>Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein αJohanna S Enke, Bradley W Schuller, Lisa Glantschnig, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2019
Novel Structured Reporting Systems for Theranostic RadiotracersRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Theranostics|May 23, 2017
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple MyelomaConstantin Lapa, Ken Herrmann, Andreas Schirbel, et al.
Clinical Nuclear Medicine|February 1, 2023
High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical DataRalph A Bundschuh, Susanne Lütje, Lena Bundschuh, et al.
Pageof 27

Showing results (221-230 of 269) with videos related to

Sort By:
Pageof 27
Theranostics|January 7, 2020
<sup>18</sup>F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular ImagingRudolf A Werner, Thorsten Derlin, Constantin Lapa, et al.
Molecular Imaging and Biology|May 30, 2019
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [<sup>18</sup>F]DCFPyL: Impact of Tumor Burden on Normal Organ UptakeRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Oncotarget|October 6, 2016
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneityRudolf A Werner, Constantin Lapa, Harun Ilhan, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine CarcinomasAlexander Weich, Rudolf A Werner, Andreas K Buck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 3, 2025
PET imaging utilization and trends in Germany: a comprehensive surveyAdrien Holzgreve, Dirk Hellwig, Henryk Barthel, et al.
Molecular Imaging and Biology|August 16, 2018
Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide TherapyRudolf A Werner, Harun Ilhan, Sebastian Lehner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2025
Biodistribution and Radiation Dosimetry for [<sup>68</sup>Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein αJohanna S Enke, Bradley W Schuller, Lisa Glantschnig, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2019
Novel Structured Reporting Systems for Theranostic RadiotracersRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Theranostics|May 23, 2017
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple MyelomaConstantin Lapa, Ken Herrmann, Andreas Schirbel, et al.
Clinical Nuclear Medicine|February 1, 2023
High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical DataRalph A Bundschuh, Susanne Lütje, Lena Bundschuh, et al.
Pageof 27